SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
Clinical Catch-Up: July 27-31
As usual, there was plenty of clinical trial news last week. Here’s a look.
July 31, 2020
 · 
6 min read
 · 
Mark Terry
Drug Development
Alexion Ends Rare Kidney Disease Program Following Poor Data
In October 2019, Alexion Pharmaceuticals snapped up Achillon Pharmaceuticals and its oral small molecule Factor D inhibitor program for a rare kidney disease for $930 million in cash. This week, the company shuttered the program following disappointing clinical data.
July 31, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
How an AI-Powered Phone App is Helping Participants During Clinical Trials
AiCure’s phone app helps clinical trials keep tabs on which participants have taken their medications correctly and which have not. By analyzing videos the app takes, they can also spot who is intentionally not taking their pills, known as intentional nonadherence.
July 30, 2020
 · 
6 min read
 · 
Chelsea Weidman Burke
Policy
Biopharma Update on the Novel Coronavirus: July 31
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 31, 2020.
July 30, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: July 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
July 29, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Pfizer and BioNTech Begin Global Phase II/III COVID-19 Vaccine Trial
The vaccine will be dosed at a 30-microgram level with a two-dose regimen. The vaccine is an mRNA product, with the mRNA encoding for the SARS-CoV-2 full length spike glycoprotein (S).
July 28, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: July 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 27, 2020.
July 24, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: July 20-24
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
July 24, 2020
 · 
8 min read
 · 
Mark Terry
Fosmanogepix showing outstanding results in phase
Drug Development
Amplyx Pharmaceuticals’ Fosmanogepix Hits the Mark in Phase II Candida Study
The company posted Phase II data that showed its experimental asset fosmanogepix demonstrated a treatment success rate of 80%.
July 24, 2020
 · 
3 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: July 24
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
July 23, 2020
 · 
4 min read
 · 
Editorial Staff
Load More
PRESS RELEASES
Drug Development
Immunis’ Phase 1/2a Clinical Trial Approved by Data Safety and Monitoring Board to Proceed with Dose Escalation
August 1, 2023
 · 
3 min read
Drug Development
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
August 1, 2023
 · 
4 min read
Drug Development
ReAlta Life Sciences Doses First Patient in Phase 2 STAR-Study of RLS-0071 for Hypoxic Ischemic Encephalopathy in Newborns
August 1, 2023
 · 
3 min read
Drug Development
IntelGenx Completes Enrollment for ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
August 1, 2023
 · 
5 min read
Drug Development
Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research
August 1, 2023
 · 
2 min read
Drug Development
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
August 1, 2023
 · 
5 min read
Drug Development
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
August 1, 2023
 · 
6 min read
Drug Development
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
August 1, 2023
 · 
8 min read
Drug Development
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
July 31, 2023
 · 
7 min read
Drug Development
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
July 31, 2023
 · 
4 min read
Drug Development
Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome
July 31, 2023
 · 
5 min read
Drug Development
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
July 31, 2023
 · 
6 min read
Drug Development
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
July 31, 2023
 · 
2 min read
Drug Development
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
July 30, 2023
 · 
5 min read
Drug Development
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
July 29, 2023
 · 
9 min read
Business
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
July 28, 2023
 · 
6 min read
Drug Development
Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836
July 27, 2023
 · 
5 min read
Drug Development
Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients
July 27, 2023
 · 
2 min read
Drug Development
Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
July 27, 2023
 · 
6 min read
Drug Development
Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)
July 27, 2023
 · 
5 min read
Load More